← 홈

Antibody

1,830개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-12 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,830개
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Daratumumab-hyaluronidase)

Myeloma Multiple · Myeloma Multiple

#MyelomaMultiple#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 3

daratumumab (Darzalex, Daratumumab/Lenalidomide/Dexamethasone for 24 months)

Multiple Myeloma in Relapse · Multiple Myeloma in Relapse

#MultipleMyelomainRelapse#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 3

daratumumab (Darzalex, Daratumumab/Lenalidomide/Dexamethasone until progression)

Multiple Myeloma in Relapse · Multiple Myeloma in Relapse

#MultipleMyelomainRelapse#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJanssenPreclinical

daratumumab (Darzalex, Daratumumab/daratumumab and hyaluronidase-fihj)

Amyloid Light-chain Amyloidosis · Amyloid Light-chain Amyloidosis

#AmyloidLight-chainAmyloidosis#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Daratumumab/rHuPH20 Co-formulation)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Daratumumab（Anti-CD38 Monoclonal Antibody）)

Immune Thrombocytopenia; Treatment · CD38

#CD38#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 1

Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Darzalex Faspro (Daratumumab and hyaluronidase-fihj))

Hematologic Malignancy; Bone Marrow Transplant Rejection · Hematologic Malignancy

#HematologicMalignancy#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 3

Daratumumab (Darzalex Faspro, Darzalex Faspro(Daratumumab))

Refractory or Relapsed Multiple Myeloma · FRα

#FR#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleAssistance Publique - Hôpitaux …Phase 2

nivolumab (Opdivo, Decreasing starting times for beginning nivolumab, Time to Event Continual Reassessment Method (TITE-CRM, Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) ))

B Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse · B Acute Lymphoblastic Leukemia

#BAcuteLymphoblasticLeukemia#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleOncoMed Pharmaceuticals, Inc.Phase 1

Demcizumab (Demcizumab)

Locally Advanced or Metastatic Solid Tumors · Locally Advanced or Metastatic Solid Tum

#LocallyAdvancedorMetastaticSolid#Antibody#Phase1#항체#면역항체+2
효능 ORR 0%임상시험 1상태 ACTIVE
AntibodystaleCedars-Sinai Medical CenterPhase 1

Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab (Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab)

Glioblastoma; Glioblastoma Multiforme · Glioblastoma

#Glioblastoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleAmgenPhase 3

AMG 162 (Denosumab, Denosumab (AMG 162))

Postmenopausal Osteoporosis · Postmenopausal Osteoporosis

#PostmenopausalOsteoporosis#Antibody#Phase3#항체#면역항체+2
효능 ORR 5%임상시험 1상태 ACTIVE
AntibodystaleAmgenPhase 2

Xgeva (Denosumab, Denosumab (Xgeva))

Bone Cyst Aneurysmal; Pathological Fracture · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 5%임상시험 1상태 ACTIVE
AntibodystaleAmgenApproved

Denosumab Prefilled Syringe [Prolia] (Denosumab Prefilled Syringe [Prolia])

Spine Deformity · Spine Deformity

#SpineDeformity#Antibody#Approved#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleCopenhagen University Hospital …Phase 3

Dexamethasone and Rituximab (Dexamethasone and Rituximab)

Idiopathic Thrombocytopenic Purpura · Idiopathic Thrombocytopenic Purpura

#IdiopathicThrombocytopenicPurpur#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleUniversity of UlmPhase 3

Dexamethasone, Rituximab, Cyclophosphamide (Dexamethasone, Rituximab, Cyclophosphamide)

Waldenström's Macroglobulinemia · Waldenström's Macroglobulinemia

#WaldenstrmsMacroglobulinemia#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleUniversity of UlmPhase 3

Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib (Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib)

Waldenström's Macroglobulinemia · Waldenström's Macroglobulinemia

#WaldenstrmsMacroglobulinemia#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystalePeking UniversityPhase 2

Dexamethasone, azacytidine, Pegaspargase, Tislelizumab (Dexamethasone, azacytidine, Pegaspargase, Tislelizumab)

NK/T Cell Lymphoma · NK/T Cell Lymphoma

#NKTCellLymphoma#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleRoche Pharma AGPhase 2

Dinutuximab beta (Dinutuximab beta)

Neuroblastoma · Relapsed Neuroblastoma

#RelapsedNeuroblastoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleFederal Research Institute of P…Phase 3

Dinutuximab beta, temozolomide, irinotecan, autologous NK cell (Dinutuximab beta, temozolomide, irinotecan, autologous NK cell)

Neuroblastoma (NB); Ganglioneuroblastoma · Neuroblastoma (NB)

#NeuroblastomaNB#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING

39 / 92 페이지

← 이전다음 →